Beam Therapeutics Inc

詳細情報 Beam Therapeutics Inc 企業名

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Beam Therapeutics Incの企業情報



企業コードBEAM

会社名Beam Therapeutics Inc

上場日Feb 06, 2020

最高経営責任者「CEO」Mr. John M. Evans

従業員数483

証券種類Ordinary Share

決算期末Feb 06

本社所在地238 Main Street

都市CAMBRIDGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02142

電話番号18573278775

ウェブサイトhttps://beamtx.com/

企業コードBEAM

上場日Feb 06, 2020

最高経営責任者「CEO」Mr. John M. Evans

Beam Therapeutics Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

Mr. Chirfi Guindo

Independent Director

--

Ms. Christi Shaw

Independent Director

--

Dr. Mark C. Fishman, M.D.

Lead Independent Director

--

Mr. Graham K. Cooper

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

収益内訳

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

データなし

地域別USD

会社名

収益

比率

United States

7.47M

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

他の

51.21%

株主統計

比率

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

他の

51.21%

種類

株主統計

比率

Investment Advisor

55.19%

Hedge Fund

20.88%

Investment Advisor/Hedge Fund

19.52%

Venture Capital

4.81%

Research Firm

3.80%

Individual Investor

1.27%

Bank and Trust

0.67%

Pension Fund

0.28%

Family Office

0.06%

機関投資家保有株



更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

537

101.17M

100.03%

+11.84M

2025Q1

562

100.13M

99.59%

+12.37M

2024Q4

542

80.18M

95.83%

-6.23M

2024Q3

539

78.60M

95.42%

-7.95M

2024Q2

538

78.23M

95.09%

-5.21M

2024Q1

550

76.09M

93.23%

-4.97M

2023Q4

549

75.48M

92.79%

-3.23M

2023Q3

554

74.84M

95.14%

-3.35M

2023Q2

566

72.06M

94.81%

-2.24M

2023Q1

583

68.81M

92.54%

-724.80K

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

7.60M

7.56%

+4.49M

+144.60%

Mar 31, 2025

ARK Investment Management LLC

8.48M

8.43%

+1.41M

+19.98%

Mar 31, 2025

Farallon Capital Management, L.L.C.

9.93M

9.87%

+1.69M

+20.50%

Mar 31, 2025

The Vanguard Group, Inc.

8.85M

8.8%

+1.24M

+16.36%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.76M

6.72%

+838.01K

+14.15%

Mar 31, 2025

Amova Asset Management Co., Ltd.

4.27M

4.24%

+309.26K

+7.81%

Mar 31, 2025

ARCH Venture Partners

4.54M

4.51%

--

Mar 31, 2025

State Street Global Advisors (US)

3.44M

3.42%

+362.74K

+11.79%

Mar 31, 2025

Bellevue Asset Management AG

2.40M

2.38%

+877.81K

+57.82%

Mar 31, 2025

Kynam Capital Management LP

2.52M

2.5%

+762.01K

+43.39%

Mar 31, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Beam Therapeutics Inc 企業名

Beam Therapeutics Incの企業情報

Beam Therapeutics Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割